- 26 are largely devoted to studies of the new oral hypoglycemic agents. In view of the fact that final evaluation of these drugs cannot be made until more is known about their mode of action, it is fitting that the leading article in each journal has been written by a basic scientist, one the Canadian physiologist, Charles H. Best, and the other the English biochemist, F. G. Young.
Therapeutic Effects
In connection with any new treatment for diabetes, it must be pointed out that, while outpatient trials are valuable and necessary, unassailable conclusions can be drawn only from studies carried out on hospitalized patients under rigidly controlled conditions with preand post-experimental periods of sufficient length, usually weeks rather than days; and even in these circumstances judgment is often difficult. The time consuming and expensive nature of such observations accounts for their scarcity. Some Canadian and British physicians have had the opportunity to conduct carefully planned investigations on inpatients, while the majority, as is true in all countries, have had to be content with office or clinic material or brief hospitalization. One has the impression that the wise precaution of using placebos during the control periods has been more widely employed in Britain than on this continent.
Taken together, the two series report a total of 245 diabetic patients, of whom all but six were treated with carbutamide (BZ-55). The majority were chosen for their probably favorable response. In judging therapeutic results it is necessary to omit thirty-three patients, some of whom were children, and others of whom * The intention in this review is to summarize interpretively the contributions in two specific journals. Reference to other investigations is not complete and will be made only when immediately relevant or necessary to round out the subject.
had interfering complications or were insufficiently studied. Of the remaining 212, a definite reduction of hyperglycemia and glycosuria, although not always to normal, was noted in 144, or 68 per cent. Because of differences in experimental design and criteria of control it is difficult to make a positive statement on an important point, namely, in what percentage of older, milder diabetics who nevertheless required insulin was it possible to keep the two-hour postprandial blood sugar below, say, 150 mg. per 100 ml. with carbutamide alone, a feat that is relatively easy to accomplish with insulin? The data would indicate that certainly less than 68 per cent, and probably less than 50 per cent, could be so controlled.
There is confirmation of the fact that the sulfonylureas are in general ineffective in patients whose disease began at a young age, who require large amounts of insulin, and who lapse into ketosis readily. These patients, as find that the response of patients to carbutamide is not related to the duration of diabetes; two of them find no relationship to body weight and one no correlation with the duration of insulin therapy or with present age. Single dose tests seemed to have limited value in predicting a favorable long-term response.
Toxicity
The average maintenance dose was from 1 to 2 gm. daily. Among the 245 patients who received the drug, 37, or 15 per cent, experienced side reactions of one sort or another. Most of these were of a minor nature, consisting of skin rash, fever, giddiness and gastrointestinal disturbance. In some cases a rash which had appeared during treatment with carbutamide disappeared gradually when tolbutamide was substituted, while in others it subsided even during continued treatment with carbutamide. One author 21 reports that granulocytopenia was the rule during the first two weeks of treatment, the neutrophiles returning to normal in some cases despite continued treatment but persisting at low levels in others. Several patients with thrombocytopenia have been observed, three 21 ' 23 with frank purpura, including one with a platelet count of 60,000 per cu. mm.
Thyroidal uptake of I 131 was diminished in the first two weeks of treatment in six patients so tested 21 but returned to normal while the drug was still being taken. One patient being treated for myxedema experienced an increase in her requirement for thyroid, 21 and in another patient hypothyroidism occurred for the first time while he was receiving carbutamide. 25 No instances of jaundice are mentioned and there were no deaths.
The incidence of toxic reactions in these studies is two to three times that observed for carbutamide in this country.- 7 The reasons for the difference are not clear. The lack of deaths is not as reassuring as it might seem. If the American experience showing approximately o.i per cent mortality 27 is any guide, 1,000 patients would have to be treated before one fatality could be expected.
Place of Sulfonylureas in Therapy
In these reports, conclusions as to the usefulness of the drugs are dominated by conservatism. While there were some patients in whom demonstrably needed insulin could be replaced by orally administered preparations, the majority of those who responded favorably could be managed with diet alone. Many authors are impressed by the toxic potential of the compounds and regard lack of knowledge of their mode of action as a deterrent to their general application. Walker 25 expresses the consensus thus: "The hypoglycaemic sulphonamides would seem to be indicated in only a comparatively small group. Until their value has been proved and their possible hazards more fully explored they cannot be recommended for widespread use."
Mechanism of Action
There is agreement that the sulfonylureas are ineffective in the known (depancreatized dog) 2 ' 3 or presumed (growth-onset diabetes in man)
23 absence of insulin. Therefore they do not act as insulin does. There remain, so far as insulin is concerned, the questions of whether its secretion is stimulated when the pancreas is present and functioning to some degree, and whether the action of whatever insulin is available, either endogenous or injected, is potentiated.
Respecting the possibility of secretory stimulation, Ashworth and Haist 8 have shown that the weight of islet tissue in rats fed carbutamide is increased over that of controls. Also favoring this hypothesis are experiments in dogs utilizing direct perfusion of the pancreas 28 and cross circulation. 29 ' 30 On the other hand, that the pancreas is not essential for the hypoglycemic action of the drugs is demonstrated by the fact that some totally depancreatized dogs maintained on suboptimal amounts of insulin experience a definite lowering of blood and urine glucose when treated chronically with carbutamide.
'
3 These observations of course exclude suppression of the alpha cells and their postulated product, glucagon, under the prevailing conditions. They are compatible with, although do not prove, a potentiation of the injected insulin, but they are also compatible with an effect on other tissues (e.g., liver) for which a minimum of insulin may be necessary. The ability of carbutamide to reduce the blood sugar or insulin requirement in the depancreatized animal maintained with insulin is inconsistent with its usual failure to do so in the juvenile diabetic patient.
17 -23 - 26 It should be noted also that in acute experiments on pancreatectomized man 31 and dog 32 no potentiation of injected insulin has been demonstrated.
If the action of the sulfonamides were either to stimulate the secretion of insulin or increase its effectiveness, it would be expected that the results of their administration would be essentially the same as if insulin itself were given. The Canadian and British scientists have added to the evidence that, aside from reduction of blood sugar and increase of liver glycogen, this is not the case. They have shown, as have others, that carbutamide does not augment the uptake of glucose or the formation of glycogen in the isolated rat diaphragm, 4 and in diabetic patients does not increase the arteriovenous blood sugar difference, 23 ' 24 diminish the rise of blood sugar after meals, 17 -21 > 22 or alter the shape of the glucose tolerance curve. 21 The blood sugar value most affected is the fasting one, and when decreased postprandial values are observed they may be traceable to the lower starting levels. Thus, it appears that carbutamide has its greatest effect on endogenous carbohydrate metabolism and little if any on the rate of disposal of ingested or injected sugar, particularly so far as muscle is concerned. There is general agreement that it does not ameliorate the ketosis of insulin deficiency, although Kinsell 33 has reported that it reduced a diet-induced hyperketonemia in a nonacidotic diabetic patient.
Other comparisons with insulin may be mentioned. Duncan 21 states that sixteen patients who were responsive to carbutamide, studied for over twenty days, showed an average reduction in daily nitrogen excretion of 2.1 gm., whereas an unresponsive group showed no change. American investigators, 34 '
35 ' 36 -37 however, have found no effect on nitrogen balance, and the preponderance of evidence is in their favor. Some of the latter, 31   -34   >  35 ' 38 moreover, have demonstrated in diabetic patients that the sulfonylureas do not produce the rise in blood pyruvate and lactate or the fall in serum phosphorus and potassium that is regularly obtained with insulin. The respiratory quotient seems to have received scant attention.
The action of these compounds on the liver has been studied extensively, but with varying results. Clarke 4 reports that when added to rabbit liver slices in vitro they diminish the output of glucose, the uptake of oxygen and the activity of cytochrome oxidase. Confirmation of reduced glucose output is provided by studies on the intact liver of man 39 and dog. 41 However, Berthet, Sutherland and Makman 42 have found that, while Orinase does inhibit the production of glucose by rabbit liver slices, the concentrations required are considerably greater than the plasma levels necessary for in vivo effects on the blood sugar. Ashmore 43 and his colleagues have reported no effect of the sulfonylureas on the appearance of glucose or disappearance of glycogen in liver slice preparations.
If the drugs did suppress hepatic glycogenolysis, a likely locus of action would be glucose-6-phosphatase. Hawkins 6 adduces evidence that the activity of this enzyme is diminished in liver homogenates from normal rats fed for three weeks on carbutamide. American workers, however, have reported either no effect 42 -44 or a slight effect 43 with high, not low, concentrations of the drugs when they were added to liver homogenates in vitro. After single parenteral doses that produced hypoglycemia in living rats the glucose-6-phosphatase activity of the liver was normal, 43 suggesting that the reduction of blood sugar was caused by something other than changes in this enzyme.
Reports of the influence of the sulfonamides on the glucagon-and adrenalin-induced release of glucose from the liver do not appear in the two journals here reviewed. In this country Vaughan 45 has found in liver slices that the compounds inhibit increased glucose production normally caused by these glycogenolytic agents, but there is abundant evidence that this effect is not obtained in the living organism. 35 The demonstration by Friedlich 7 that carbutamide interferes with glucose absorption in the rat is interesting, but admittedly it is not sufficient to explain the lowering of blood sugar, especially in view of the fact that this effect is exerted chiefly on the fasting levels.
Finally, Young 20 makes an interesting suggestion. He points out that certain guanidine derivatives, acridine, sulfonamides and penicillin all have some hypoglycemic as well as antimicrobial properties. Recalling the finding of Markowitz and Rappaport (Physiol. Rev. 31:188, 1951 ) that penicillin prevents the usually fatal outcome of hepatic artery ligation in dogs, and the further fact that the liver of many species normally contains anaerobic bacteria which may account for death in such dogs when untreated, he postulates that the sulfonylureas may act by inhibiting certain flora of the liver that normally destroy insulin. While this might explain the action of carbutamide, it would not clarify that of tolbutamide, and Young suggests that metabolic derivatives of the latter may be bacteriostatic whereas the parent substance is not. There is much evidence, however, to indicate that inhibition of insulin degradation is not the only way, if indeed it is a way at all, in which the sulfonylureas exert their hypoglycemic effect. SUMMARY British and Canadian experience with the sulfonylureas is in agreement with that of others that these compounds are inoperative in patients who experience ketosis readily with deprivation of insulin and are most effective in older patients with mild diabetes. Of these, the group in which the established need for insulin can be fully met by the sulfonamides is probably not large. Evidence is presented that, contrary to earlier reports, response is not related to body weight or to duration of diabetes or insulin treatment. The over-all incidence of side effects has been 15 per cent. Most of these were not serious, but disturbing hematologic disturbances were encountered in some cases.
It has not been possible to prove that any single organ or biochemical system is the sole site of action of these substances. The only solid fact is that the presence of insulin is essential. A number of possibilities have been excluded. Apparently the drugs do not facilitate the peripheral utilization of glucose even when insulin is available. They lower the blood sugar in the absence of the pituitary, the adrenals and the pancreatic alpha cells, and even in the absence of the beta cells when insulin is injected; but this does not necessarily mean that they have no effect on these tissues in the intact organism, and for the pancreas at least this remains a distinct possibility. Some effect on the liver seems established, if only because some toxic reactions are traceable to that organ, but the physiologic and chemical mechanisms involved are still unclear. It is not likely that the moderate suppression of thyroid function or intestinal absorption is sufficient to account for the reduction of blood sugar levels. 
THE ORAL HYPOGLYCEMIC SULFONYLUREA COMPOUNDS
The Editors of this Journal have viewed with great interest the developing knowledge concerning the hypoglycemic sulfonylurea compounds. The mechanism of their action is not yet clear in man or laboratory animals and much controversial evidence has been accumulated concerning a role in stimulating pancreatic secretion of insulin and the potentiation of exogenous insulin even in the pancreatectomized subject. The need for long-term studies, including the search for remote toxicologic effects in experimental diabetes and human diabetes seems self-evident. All physicians hope for a cure as well as protective action in diabetics against some of the ophthalmic, cardiorenal and neurologic complications. This will require years of testing for adequate appraisal.
Meanwhile we question the wisdom of widespread clinical administration of the sulfonylurea drugs except under rigidly controlled conditions followed by careful evaluation. The well-known ameliorative effect of merely having diabetic patients report more frequently and more regularly to their physicians makes evaluation of therapeutic results in ambulatory patients difficult. Reduced glucosuria and a return to "normoglycemic" blood levels may follow food restriction incident to drug administration, or without it, if patients add a little more care and are reassured.
Duncan and others both here and abroad have noted even in those patients who initially respond favorably to the oral hypoglycemic compounds, that the beneficial effects so far as glucosuria and hyperglycemia are concerned may disappear after five or six months on the oral hypoglycemic drug. This raises new questions: Are these patients becoming drug fast? More careless about their diets? Or are they obtaining poor control because they have been misled into believing that their diabetes was "cured" or needed less attention?
The risk to the lean diabetic patients subject to keto-acidosis on discontinuing insulin is so great that it seems mandatory to us that such patients be hospitalized for closer observation during trials of the drug.
Should the hypoglycemic agents be given to the overweight patient with mild or moderately severe diabetes? Why? Are we not obliged to recommend reduction of caloric intake for each of these subjects anyway? Are these compounds, like insulin, likely to lead to increased ingestion of food? That they cause hypoglycemia is not in question, even though this effect is inconstant. Even if they prove to have anabolic effects, do not weight reduction and calorie adjustment come first? At the moment it seems as if they are most effective where we do not need them, namely in the adult who is overweight and mildly diabetic. The sick, acidotic diabetic patient still needs insulin.
It is deplorable that information has been disseminated to create the false hope that diabetes is now an easily controlled disease because "tablets" are available. Our sickest diabetics are in no way helped by these compounds. And only some (albeit a majority) of mild diabetic patients are "helped" at all. It is deplorable that some announcements of benefit have been based on short preliminary observations without details of study or the use of suitable controls. It is to be hoped that all investigators of clinical diabetes will ponder the need for rigid selection of subjects under equally rigid supervision before administering the drug haphazardly.
The pharmaceutical companies concerned with the development of these compounds will as a matter of enlightened self-interest and public concern discourage the administration of the drugs to patients who do not need them or who, as in the case of the obese, may be defeated in attaining their goal of better health, lower weight and more normal metabolic balance. These companies have so far done a commendable job in the research and testing which is continuing in a cooperative manner with the investigators in the field of diabetes.
The development and marketing of insulin was achieved with the welfare of the diabetic patient carefully guarded by the clinical investigators and the manufacturers. The education of the physician and the patient towards effective management of diabetes is the finest form of regulation that medicine has offered for any disease. It is not yet in the interest of good medicine and the well-being of diabetic patients to support the release for marketing of an "insulin substitute" before adequate clinical testing and appraisal have been completed.
